Publications by authors named "W Hinrichs"
Article Synopsis
- Increasing resistance to current antiviral drugs for influenza highlights the need for new treatments, focusing on both drug development and administration methods.
- CD-6'SLN, a novel entry inhibitor that mimics sialic acid, was formulated into a dry powder using spray drying with a dispersion enhancer, ensuring stability and efficacy in a dry powder inhaler.
- In tests on infected mice, the aerosolized CD-6'SLN significantly reduced disease severity and inflammation compared to control groups, demonstrating its potential as a new treatment for influenza.
Article Synopsis
- * Recent advancements in the field include the approval of boronate-based β-lactamase inhibitors for treating multidrug-resistant bacteria, emphasizing the need for effective solutions.
- * Researchers used time-resolved serial crystallography to gain insights into the binding mechanisms of β-lactamase CTX-M-14, collecting detailed data that enhances the understanding of enzymatic reactions and resistance.
Article Synopsis
- The main protease (M) of SARS-CoV-2 is crucial for the virus's functionality and is considered a potential target for drug development, as it is only active in its reduced form.
- When oxidized, M's activity halts but can be restored, indicating an evolutionary adaptation to oxidative environments, although the protective mechanisms haven't been fully elucidated.
- Researchers determined the crystal structure of oxidized M, revealing a disulfide bond that affects its dimer stability and crystallization, providing insights into the protein's response to oxidative stress and its structural study conditions.*
Background: Lung fibrosis is a chronic lung disease with a high mortality rate with only two approved drugs (pirfenidone and nintedanib) to attenuate its progression. To date, there are no reliable biomarkers to assess fibrosis development and/or treatment effects for these two drugs. Osteoprotegerin (OPG) is used as a serum marker to diagnose liver fibrosis and we have previously shown it associates with lung fibrosis as well.
View Article and Find Full Text PDFArticle Synopsis
- Emerging RNA viruses like SARS-CoV-2 pose significant health risks, with the virus entering cells through pathways that rely on cysteine cathepsins, particularly cathepsin L (CatL), a potential target for treatment.
- * Researchers explored a range of inhibitors targeting CatL, finding that compounds such as Calpain inhibitor XII and MG-101 show strong antiviral effects at very low concentrations in specific cell lines.
- * The study also revealed an off-target effect of some inhibitors and provided detailed crystal structures of CatL, which can help in designing better drug candidates against protease-related diseases.